NewsRamp Psychedelics Podcast

Explore the emerging world of psychedelics with the 'NewsRamp Psychedelics Podcast.' This podcast delivers the latest news and insights from NewsRamp.com, focusing on research developments, therapeutic applications, and regulatory changes in the psychedelics field. Stay informed on the groundbreaking advancements in this evolving industry.

Promising Results from Beckley Psytech's ELE-101 Phase 1 Trial for Major Depressive Disorder

In this episode, Atai Life Sciences co-founder and co-CEO Florian Brand discusses the promising initial results from Beckley Psytech's phase 1 trial of ELE-101 for major depressive disorder. ELE-101, an IV formulation of psilocin, aims to shorten treatment duration to two hours, with good tolerance and safety shown in phase one trials. The phase 2 trial is underway with data expected later this year. Brand also highlights the potential benefits of the two-hour treatment model for other compounds in development for depression treatment.

Published: 2024-06-26 07:33:22

Duration: 00:02:09

Exploring Ibogaine: A Breakthrough in Addiction Therapy with Deborah Mash, PhD

Join neuroscientist Deborah Mash, PhD, on 'Psychedelic Breakthrough Addiction Therapy' as she explores cutting-edge research on breakthrough addiction therapies, focusing on psychedelic medicines like Ibogaine. Dr. Mash, with thirty years of experience in addiction neuroscience, offers insight into groundbreaking therapies with the potential to transform lives. Tune in to CannabisRadio.com to learn more about the renaissance of psychedelic therapy for addiction treatment.

Published: 2024-06-25 15:23:52

Duration: 00:02:00

Exploring the Future of Psychedelic Therapy with Tryptamine Therapeutics Inc.

Join host Jonathan Jackson as he speaks with Tryptamine Therapeutics Inc. CEO Jason Carroll about the company's recent debut on the Australian Securities Exchange. Tryptamine Therapeutics is focused on developing an intravenous-infused psilocin formulation for psychedelic therapy, with core programs like TRP-8803 and TRP-8802 showing promising results in trials for conditions like fibromyalgia, IBS, and BED. Backed by a qualified Board and research partnerships, the company is set to begin groundbreaking clinical trials in Australia this quarter.

Published: 2024-06-05 13:07:25

Duration: 00:02:08